Research Article: Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide- Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
Introduction:
Diabetes is a major threat to human health worldwide. The International Diabetes Federation (IDF) has listed approximately million adults with diabetes in , a number expected to increase to million by . Glucagon-like peptide- receptor (GLP-R) agonists have shown remarkable therapeutic effects for type diabetes mellitus (TDM). , Furthermore, GLP-R agonists have multiple biological effects that can treat obesity, cardiovascular, neurological, metabolic diseases and play a positive role in tumor therapy.
Read more